New Delhi, Jul 31 (PTI) Mankind Pharma on Thursday reported a 17 per cent decline in consolidated profit after tax (PAT) at Rs 445 crore for the June quarter.
The drug maker posted a PAT of Rs 538 crore for the April-June quarter of the last fiscal year.
Revenue from operations rose to Rs 3,570 crore for the first quarter as compared to Rs 2,868 crore in the year-ago period, Mankind Pharma said in a statement.
The company said its board has approved the raising of up to Rs 1,000 crore through unsecured funding instruments, including issuance of commercial papers, on a private placement basis, in one or more tranches.
The board also approved interim dividend of Re 1 per share on face value of Re 1 per share for 2025-26.
The company said its board has approved the acquisition of the branded generic business relating to women health portfolio of Bharat Serums and Vaccines Ltd through slump sale on a going concern basis.
Shares of the company on Thursday ended 0.28 per cent down at Rs 2,567.75 apiece on the BSE.
Mankind Pharma Q1 falls 17 pc to Rs 445 cr
PTI
Updated: July 31, 2025 19:18 IST
(This story has not been edited by THE WEEK and is auto-generated from PTI)
